Replimune Group (FRA:7R8) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group OCF Margin %?

Replimune Group FRA:7R8 -3.56% 32 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 949 Biotechnology companies, Replimune Group ranks worse than 105373.97% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Replimune Group's Cash Flow from Operations for the three months ended in Mar. 2026 was €-48.58 Mil. Replimune Group's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Replimune Group's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Replimune Group's current OCF Yield % is -30.06%.

The historical rank and industry rank for Replimune Group's OCF Margin % or its related term are showing as below:


FRA:7R8's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Replimune Group OCF Margin % Related Terms

Replimune Group OCF Margin % Historical Data

* Premium members only.

The historical data trend for Replimune Group's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Replimune Group OCF Margin % Chart

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Replimune Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Replimune Group's OCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-242.498/0
= %

Replimune Group's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-48.579/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Replimune Group (FRA:7R8) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #999999 out of 949 companies in the Biotechnology industry.
Is Replimune Group's OCF Margin % too high?
Replimune Group's current OCF Margin % is 0.00%. Based on the distribution chart, Replimune Group ranks #999999 out of 949 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's OCF Margin % compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #999999 out of 949 companies for OCF Margin %. This places Replimune Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Replimune Group and its competitors. Replimune Group's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price